ArticleDermatologic therapy2020
Antipsoriatic treatments during COVID-19 outbreak.
Article in Dermatologic therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review.Dermatologic therapy · 2020Pooled it
- The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients.Advances in experimental medicine and biology · 2023Article
- Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.Journal of clinical medicine · 2022Review
- Biologics for Psoriasis during the COVID-19 Pandemic.Journal of clinical medicine · 2021Review
- Comment on "Psoriasis, COVID-19, and acute respiratory distress syndrome: Focusing on the risk of concomitant biological treatment".Dermatologic therapy · 2020Article
- Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.Viruses · 2020Review
- Biologic therapy for psoriasis during the COVID-19 outbreak: The choice is to weigh risks and benefits.Dermatologic therapy · 2020Article
- Comment on "Antipsoriatic treatments during COVID-19 outbreak".Dermatologic therapy · 2020Article
- COVID-19 and dermatology: a comprehensive guide for dermatologists.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Review
- Moderate-to-severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak.Dermatologic therapy · 2020Observational
- Covid-19 infection in psoriasis patients treated with cyclosporin.Dermatologic therapy · 2020Article
- Harnessing Memory NK Cell to Protect Against COVID-19.Frontiers in pharmacology · 2020Review
- Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?Clinics in dermatologyReview
Corrections and comments
- Commented on by
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.